ABSTRACT
Background: Oncology patients, with active, lung, metastatic (m) disease, 1st y after diagnosis, have higher risk of SARS-COV2 infection, 26% severity/mortality vs 2-3% overall. Individual risk depends from age, comorbidity, PS. Infection impaired diagnosis/surveillance. Population includes patients with active early (E) or m disease on treatment (OT), untreated m and long survivors. mRNAbased vaccines demonstrated >90% efficacy to prevent disease. Immunization level depends from tumors/sites, therapy, administration timing, immune dysfunction and fitness. Adverse events were local reaction, systemic reactivity, asthenia, headache and pyrexia. Methods: We reported prevalence of infection/disease, ongoing vaccine administrations among patients followed at Oncology Territorial Care, S. Salvatore Hospital L'Aquila. Results: 18 patients reported infection, 8 asymptomatic, 2 mild symptoms (pyrexia), 8 severe (bilateral pneumonia, fever, respiratory failure, 6 hospitalized): 9 OT, 2 m colorectal, 1 m pancreatic, 1 m ovarian, 1 m neuroendocrine, 1 m renal cell, 1 pancreatic with previous m colorectal, 2 E colorectal (3 chemotherapy/target agents, 1 chemotherapy, 2 biological agent, 2 surgery, 1 locoregional therapy);8 survivor, 3 with history of m;1 with active disease before treatment beginning. 5 thereafter received 1 vaccine dose. From 4thJan to 20thMay 2021, 194 patients (87 M, 107 F) underwent vaccine administration, 24 affected by E disease OT, 64 m OT, 1 m out of treatment, 105 survivors. Tumors: 18 lung (11 m, 2 E OT), 64 gastrointestinal (19 m, 6 E OT), 33 breast (9 m, 2 E OT), 20 genitourinary (8 m, 2 E OT), 5 cutaneous/melanoma (3 m OT), 20 gynecological (6 m, 2 E OT), 6 HN (3 m, 1 E OT), 5 CNS, 17 multiple (1 m, 6 E OT), 6 rare (3 m, 1 E OT). Administered vaccines: 106 Pfizer-BioNTech, 17 Moderna, 4 Astra Zeneca. All grade adverse events: pain at injection site, 37, fever 9, asthenia 8, myalgia/articolar pain 7, headache 3, diarrhea 1, erythema 1, vomiting 1, hypertension 1, conjunctival hemorrhage1, hemolitic syndrome, 1. Conclusion: Open questions are long-term efficacy, protection again mild/ severe infection, immunity in aged, contagiousness of vaccinated patients, intervals between administrations. Vaccination in oncology population prevents frail patients from infection and severe disease, monitoring in clinical practice safety/effectiveness, not included in trials. Mature data will be presented.